TCGA-HQ-A5NE-01A-12R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.15505913
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.600
- INTERFERON_ALPHA_RESPONSE+0.480
- E2F_TARGETS+0.470
- MITOTIC_SPINDLE+0.470
- PROTEIN_SECRETION+0.460
- INFLAMMATORY_RESPONSE+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- KRAS_SIGNALING_UP+0.420
- G2M_CHECKPOINT+0.400
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.220
- BILE_ACID_METABOLISM-0.190
- SPERMATOGENESIS-0.150
- KRAS_SIGNALING_DN-0.110
- OXIDATIVE_PHOSPHORYLATION-0.070
- CHOLESTEROL_HOMEOSTASIS-0.030
- MYOGENESIS-0.020
- PEROXISOME-0.020
- ADIPOGENESIS+0.000
- FATTY_ACID_METABOLISM+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9T4-01A-11R-A39I-07 | — | — | 0.927 |
| 2 | TCGA-70-6722-01A-11R-1820-07 | — | cohortSQ1 | 0.926 |
| 3 | SRR934816 | — | — | 0.917 |
| 4 | SRR934782 | — | — | 0.912 |
| 5 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.911 |
| 6 | C9EE359E-2F42-4D20-880D-FBF8B4953731 | — | — | 0.910 |
| 7 | 2DAB6792-F9AF-4565-BDD5-C9802F3132F4 | — | — | 0.909 |
| 8 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.905 |
| 9 | SRR934963 | — | — | 0.904 |
| 10 | SRR934825 | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.390 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |